NasdaqGS - Nasdaq Real Time Price USD

Valneva SE (VALN)

Compare

4.5400

-0.1100

(-2.37%)

At close: January 10 at 4:00:01 PM EST

4.5400

0.00

(0.00%)

After hours: January 10 at 4:59:38 PM EST

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Saint Herblain (France), January 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 43nd Annual J.P. Morgan Healthcare Conference, January 13-15, 2025 in San Francisco. Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss the Company’s commercial portfolio of vaccines, which

GlobeNewswire 4 days ago

INRLF

VALN
-2.37%
VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA Declaration of shares and voting rights December 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: January 3, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this chang

GlobeNewswire 7 days ago

INRLF

VALN
-2.37%
Exploring High Growth Tech Stocks for December 2024

As global markets experience fluctuations, with U.S. stocks facing declines due to cautious Federal Reserve commentary and political uncertainty, the focus on high growth tech stocks becomes particularly relevant for investors seeking potential opportunities amidst broader market volatility. In such an environment, identifying a promising stock often involves looking at companies with innovative technologies and strong growth prospects that can navigate economic challenges and capitalize on...

Simply Wall St. 18 days ago

INRLF

VALN
-2.37%
Valneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia

Valneva ( (VALN) ) just unveiled an announcement. Valneva has entered into a significant collaboration with the Serum Institute of India (SII) to expand the reach of its single-shot chikungunya vaccine in Asia amidst a severe outbreak in India. This exclusive license agreement will allow broader access to the vaccine, particularly in low-and-middle-income countries, backed by a $41.3 million funding agreement with CEPI and the European Union. The partnership will involve a technology transfer fo

TipRanks 22 days ago

INRLF

VALN
-2.37%
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

Saint-Herblain (France), Pune, (India), December 19, 2024 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses, today announced an exclusive license agreement for Valneva’s single-shot chikungunya vaccine that enables supply of the vaccine in Asia. The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the

GlobeNewswire 23 days ago

INRLF

VALN
-2.37%
VALNEVA - Declaration of shares and voting rights: November 30, 2024

VALNEVA Declaration of shares and voting rights November 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 5, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this ch

GlobeNewswire last month

INRLF

VALN
-2.37%
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Saint-Herblain (France), December 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the publication of an article on the global health and economic burden of mosquito-borne disease chikungunya in The British Medical Journal (BMJ), one of the world’s leading peer-reviewed medical journals. The article, titled, “The Global Health and Economic Burden of Chikungunya from 2011 to 2020: A Model-Driven Analysis on the Impact of an Emerging Vector-Bor

GlobeNewswire last month

INRLF

VALN
-2.37%
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults Saint-Herblain (France), December 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this va

GlobeNewswire last month

INRLF

VALN
-2.37%
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock

The FDA application complements recent label extension submissions to the EMA and Health Canada, highlighting Valneva's strategic push to enhance IXCHIQ's global reach.

Zacks last month

VLA.PA
+4.73%
GMED

HAE
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the U.S. Food and Drug Administration (FDA) to potentially extend the use of its chikungunya vaccine IXCHIQ®, which is currently approved in adults, to adolescents aged 12 to 17 years. The application also includes adding the two-y

GlobeNewswire last month

INRLF

VALN
-2.37%
High Growth Tech Stocks To Explore This November 2024

As global markets experience broad-based gains with smaller-cap indexes outperforming large-caps, investors are closely watching the Federal Reserve's upcoming decisions on interest rates amid a strong U.S. labor market and rising home sales. In this environment, identifying high growth tech stocks involves focusing on companies that can capitalize on technological advancements and maintain robust performance despite geopolitical tensions and economic uncertainties.

Simply Wall St. last month

STRYF

INRLF

VALN
-2.37%
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Shares in European vaccine makers tumbled after President-elect Donald Trump picked vaccine sceptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

The Wall Street Journal last month

INRLF

VALN
-2.37%
BVNKF
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate shigellosis vacci

GlobeNewswire last month

INRLF

VALN
-2.37%
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Saint-Herblain (France), November 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming cat

GlobeNewswire last month

INRLF

VALN
-2.37%
Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

Valneva SE (INRLF) reports a significant turnaround with increased sales and a positive operating profit, despite challenges in the US market.

GuruFocus.com 2 months ago

VLA.PA
+4.73%
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to th

GlobeNewswire 2 months ago

INRLF

VALN
-2.37%
VALNEVA - Declaration of shares and voting rights: October 31, 2024

VALNEVA Declaration of shares and voting rights October 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: November 6, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this chang

GlobeNewswire 2 months ago

INRLF

VALN
-2.37%
High Growth Tech Stocks in France to Watch October 2024

As the European Central Bank's recent interest rate cuts have buoyed major stock indexes, France's CAC 40 Index has seen a modest increase, reflecting a cautiously optimistic market sentiment amid ongoing monetary easing. In this environment, investors may find it beneficial to focus on high-growth tech stocks that demonstrate strong fundamentals and adaptability in a rapidly evolving economic landscape.

Simply Wall St. 2 months ago

INRLF

VALN
-2.37%
OVHFF
Lectra And 2 Other High Growth Tech Stocks In France

As the European Central Bank's recent rate cuts have spurred optimism for further monetary easing, France's CAC 40 Index has seen a modest rise, reflecting broader positive sentiment across major European markets. In this environment of potential economic support and easing inflationary pressures, high-growth tech stocks in France like Lectra are gaining attention for their innovative capabilities and strong market positioning.

Simply Wall St. 2 months ago

LCTSF

OVHFF

OVHGY
Exploring 3 High Growth Tech Stocks In France

As the European Central Bank's recent interest rate cuts have buoyed major stock indexes, France's CAC 40 Index has seen a modest rise, reflecting a broader optimism in the region’s economic outlook. In this environment of monetary easing and improved market sentiment, identifying high-growth tech stocks involves looking for companies that can leverage innovation to capitalize on these favorable conditions while demonstrating resilience and adaptability in their business models.

Simply Wall St. 2 months ago

VIVHY

VVVNF

INRLF

Performance Overview

Return	VALN	CAC 40
YTD	+5.09%	+1.61%
1-Year	-56.97%	+0.06%
3-Year	-88.62%	+2.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Valneva SE (VALN)

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

VALNEVA Declaration of shares and voting rights: December 31, 2024

Exploring High Growth Tech Stocks for December 2024

Valneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

VALNEVA - Declaration of shares and voting rights: November 30, 2024

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

High Growth Tech Stocks To Explore This November 2024

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

VALNEVA - Declaration of shares and voting rights: October 31, 2024

High Growth Tech Stocks in France to Watch October 2024

Lectra And 2 Other High Growth Tech Stocks In France

Exploring 3 High Growth Tech Stocks In France

Performance Overview